{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:06:04Z","timestamp":1789005964497,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Wu Jieping Medical Foundation of China","award":["H011211, H011212"],"award-info":[{"award-number":["H011211, H011212"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-05000-w","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:04:24Z","timestamp":1782374664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of adjuvant somatostatin analogue therapy with disease-free survival in patients with gastroenteropancreatic neuroendocrine tumours: a Chinese multi-institutional propensity score matched and weighted analysis (CASSANET-GEP)"],"prefix":"10.1186","volume":"24","author":[{"given":"Huike","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meichen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihebali","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"5000_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1210\/endrev\/bnz004","volume":"41","author":"J Hofland","year":"2020","unstructured":"Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41:371\u2013403.","journal-title":"Endocr Rev"},{"key":"5000_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335\u201342.","journal-title":"JAMA Oncol"},{"key":"5000_CR3","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","volume":"31","author":"G Rindi","year":"2018","unstructured":"Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International agency for research on cancer (IARC) and world health organization (WHO) expert consensus proposal. Mod Pathol. 2018;31:1770\u201386.","journal-title":"Mod Pathol"},{"key":"5000_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA, Nothing But NET. A review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19:991\u20131002.","journal-title":"Neoplasia."},{"key":"5000_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33:115\u201354.","journal-title":"Endocr Pathol"},{"key":"5000_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000080731","volume":"80","author":"BG Taal","year":"2004","unstructured":"Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80:3\u20137.","journal-title":"Neuroendocrinology."},{"key":"5000_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01029-7","volume":"23","author":"S Das","year":"2021","unstructured":"Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep. 2021;23:43.","journal-title":"Curr Oncol Rep"},{"key":"5000_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000443171","volume":"103","author":"M Falconi","year":"2016","unstructured":"Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103:153\u201371.","journal-title":"Neuroendocrinology."},{"key":"5000_CR9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844\u201360.","journal-title":"Ann Oncol"},{"key":"5000_CR10","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Neuroendocrine and Adrenal Tumors, Version 1.2026. Plymouth Meeting (PA): NCCN; 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf. Accessed 06 Jun 2026."},{"key":"5000_CR11","unstructured":"Chinese Society of Clinical Oncology (CSCO). CSCO Clinical Practice Guidelines in Oncology for Neuroendocrine Neoplasms 2024. Beijing China: PEOPLE\u2019S MEDICAL PUBLISHING HOUSE; 2024."},{"key":"5000_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/SLA.0b013e31824e6108","volume":"256","author":"JR Strosberg","year":"2012","unstructured":"Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012;256:321\u20135.","journal-title":"Ann Surg"},{"key":"5000_CR13","first-page":"70","volume":"10","author":"F Costa","year":"2014","unstructured":"Costa F, Gumz B. Octreotide - a review of its use in treating neuroendocrine tumours. Eur Endocrinol. 2014;10:70\u20134.","journal-title":"Eur Endocrinol"},{"key":"5000_CR14","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:1556\u20137.","journal-title":"N Engl J Med"},{"key":"5000_CR15","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/ijms21051682","volume":"21","author":"M Gomes-Porras","year":"2020","unstructured":"Gomes-Porras M, C\u00e1rdenas-Salas J, \u00c1lvarez-Escol\u00e1 C. Somatostatin analogs in clinical practice: a review. Int J Mol Sci. 2020;21:1682.","journal-title":"Int J Mol Sci"},{"key":"5000_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s12020-020-02475-2","volume":"71","author":"ME Caplin","year":"2021","unstructured":"Caplin ME, Pavel M, Phan AT, \u0106wik\u0142a JB, Sedl\u00e1\u010dkov\u00e1 E, Thanh XT, et al. Lanreotide autogel\/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021;71:502\u201313.","journal-title":"Endocrine."},{"key":"5000_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ejca.2021.06.056","volume":"157","author":"M Pavel","year":"2021","unstructured":"Pavel M, \u0106wik\u0142a JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur J Cancer. 2021;157:403\u201314.","journal-title":"Eur J Cancer"},{"key":"5000_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000443612","volume":"104","author":"A Rinke","year":"2017","unstructured":"Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 2017;104:26\u201332.","journal-title":"Neuroendocrinology."},{"key":"5000_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/01.sla.0000232556.24258.68","volume":"245","author":"PG Schurr","year":"2007","unstructured":"Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg. 2007;245:273\u201381.","journal-title":"Ann Surg"},{"key":"5000_CR20","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.surg.2003.07.025","volume":"134","author":"JA Norton","year":"2003","unstructured":"Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057\u201363. discussion 63-5","journal-title":"Surgery."},{"key":"5000_CR21","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","volume":"15","author":"A Frilling","year":"2014","unstructured":"Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8\u201321.","journal-title":"Lancet Oncol"},{"key":"5000_CR22","first-page":"85","volume":"35","author":"Association SoNNoCA-C","year":"2025","unstructured":"Association SoNNoCA-C. China anti-cancer association guideline for diagnosis and treatment of neuroendocrine neoplasms (2025 edition). China Oncology. 2025;35:85\u2013142.","journal-title":"China Oncology"},{"key":"5000_CR23","first-page":"161","volume":"5","author":"EM Wolin","year":"2012","unstructured":"Wolin EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res. 2012;5:161\u20138.","journal-title":"Gastrointest Cancer Res"},{"key":"5000_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1210\/jc.2011-2088","volume":"97","author":"C Bousquet","year":"2012","unstructured":"Bousquet C, Lasfargues C, Chalabi M, Billah SM, Susini C, Vezzosi D, et al. Clinical review: current scientific rationale for the use of somatostatin analogs and mtor inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab. 2012;97:727\u201337.","journal-title":"J Clin Endocrinol Metab"},{"key":"5000_CR25","first-page":"831","volume":"6","author":"WY Zhao","year":"2014","unstructured":"Zhao WY, Zhuang C, Xu J, Wang M, Zhang ZZ, Tu L, et al. Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy. Am J Transl Res. 2014;6:831\u201340.","journal-title":"Am J Transl Res"},{"key":"5000_CR26","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1158\/1535-7163.MCT-23-0029","volume":"22","author":"G Han","year":"2023","unstructured":"Han G, Hwang E, Lin F, Clift R, Kim D, Guest M, et al. RYZ101 (Ac-225 DOTATATE) opportunity beyond gastroenteropancreatic neuroendocrine tumors: preclinical efficacy in small-cell lung cancer. Mol Cancer Ther. 2023;22:1434\u201343.","journal-title":"Mol Cancer Ther"},{"key":"5000_CR27","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/1097-0142(19921101)70:9<2268::AID-CNCR2820700910>3.0.CO;2-X","volume":"70","author":"G Viale","year":"1992","unstructured":"Viale G, Doglioni C, Gambacorta M, Zamboni G, Coggi G, Bordi C. Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer. 1992;70:2268\u201377.","journal-title":"Cancer"},{"key":"5000_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54599-4","volume":"14","author":"JY Kim","year":"2024","unstructured":"Kim JY, Kim J, Kim YI, Yang DH, Yoo C, Park IJ, et al. Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors. Sci Rep. 2024;14:4047.","journal-title":"Sci Rep"},{"key":"5000_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17474124.2017.1253473","volume":"11","author":"D Tamburrino","year":"2017","unstructured":"Tamburrino D, Partelli S, Renzi C, Crippa S, Muffatti F, Perali C, et al. Systematic review and meta-analysis on laparoscopic pancreatic resections for neuroendocrine neoplasms (PNENs). Expert Rev Gastroenterol Hepatol. 2017;11:65\u201373.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"5000_CR30","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1136\/jclinpath-2014-202515","volume":"67","author":"S La Rosa","year":"2014","unstructured":"La Rosa S, Vanoli A. Gastric neuroendocrine neoplasms and related precursor lesions. J Clin Pathol. 2014;67:938\u201348.","journal-title":"J Clin Pathol"},{"key":"5000_CR31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/cncr.31124","volume":"124","author":"A Dasari","year":"2018","unstructured":"Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 2018;124:807\u201315.","journal-title":"Cancer."},{"key":"5000_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1196\/annals.1329.033","volume":"1030","author":"A Massa","year":"2004","unstructured":"Massa A, Barbieri F, Aiello C, Iuliano R, Arena S, Pattarozzi A, et al. The phosphotyrosine phosphatase eta mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1\/2. Ann N Y Acad Sci. 2004;1030:264\u201374.","journal-title":"Ann N Y Acad Sci"},{"key":"5000_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000493318","volume":"108","author":"H Sorbye","year":"2019","unstructured":"Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, et al. Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Neuroendocrinology. 2019;108:54\u201362.","journal-title":"Neuroendocrinology."},{"key":"5000_CR34","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1097\/MPA.0000000000002425","volume":"54","author":"MG Maratta","year":"2025","unstructured":"Maratta MG, Chiloiro S, Raia S, Maiorano BA, Horn G, Brizi MG, et al. Somatostatin analogs versus active surveillance in small pancreatic neuroendocrine tumors. Pancreas. 2025;54:e524\u2013e9.","journal-title":"Pancreas."},{"key":"5000_CR35","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3390\/metabo12111057","volume":"12","author":"R Modica","year":"2022","unstructured":"Modica R, La Salvia A, Liccardi A, Cannavale G, Minotta R, Benevento E, et al. Lipid metabolism and homeostasis in patients with neuroendocrine neoplasms: from risk factor to potential therapeutic target. Metabolites. 2022;12:1057.","journal-title":"Metabolites."},{"key":"5000_CR36","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.3390\/biomedicines9121810","volume":"9","author":"MI Del Olmo-Garcia","year":"2021","unstructured":"Del Olmo-Garcia MI, Prado-Wohlwend S, Andres A, Soriano JM, Bello P, Merino-Torres JF. Somatostatin and somatostatin receptors: from signaling to clinical applications in neuroendocrine neoplasms. Biomedicines. 2021;9:1810.","journal-title":"Biomedicines."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05000-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05000-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05000-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:07:33Z","timestamp":1789002453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05000-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5000"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05000-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for this retrospective cohort study was obtained from the Ethics Committee of National Cancer Center\/Cancer Center Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Approval Number: 25\/324-5270) on 8 July 2025. The committee waived the requirement for informed consent due to the retrospective design of the study, which involved the analysis of anonymized existing data. All procedures were performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"483"}}